• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.在感染的THP-1单核细胞模型中,抗生素组合对铜绿假单胞菌耐药菌株的活性。
Antimicrob Agents Chemother. 2015 Jan;59(1):258-68. doi: 10.1128/AAC.04011-14. Epub 2014 Oct 27.
2
Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.美罗培南联合或不联合环丙沙星及黏菌素对铜绿假单胞菌和鲍曼不动杆菌的活性。
Antimicrob Agents Chemother. 2008 Jan;52(1):333-6. doi: 10.1128/AAC.00689-07. Epub 2007 Oct 29.
3
Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of .头孢他啶-阿维巴坦联合不同抗生素对多黏菌素耐药临床分离株的协同作用。
Infect Dis (Lond). 2020 Sep;52(9):616-624. doi: 10.1080/23744235.2020.1767803. Epub 2020 May 19.
4
Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.黏菌素联合美罗培南组合对广泛耐药铜绿假单胞菌(包括高危克隆)具有协同体外活性。
J Glob Antimicrob Resist. 2019 Sep;18:37-44. doi: 10.1016/j.jgar.2019.04.012. Epub 2019 May 30.
5
Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.美罗培南与环丙沙星对从重症监护病房感染中分离出的铜绿假单胞菌和不动杆菌菌株的协同作用研究。
Scand J Infect Dis. 2001;33(11):818-21. doi: 10.1080/00365540110027222.
6
In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.非传统抗菌药物单独或联合使用对从重症监护病房分离出的多重耐药铜绿假单胞菌和鲍曼不动杆菌菌株的体外活性。
Int J Antimicrob Agents. 2006 Mar;27(3):224-8. doi: 10.1016/j.ijantimicag.2005.10.012. Epub 2006 Feb 7.
7
Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing.噬菌体-抗生素联合治疗多重耐药铜绿假单胞菌:体外协同试验。
J Appl Microbiol. 2022 Sep;133(3):1636-1649. doi: 10.1111/jam.15647. Epub 2022 Jun 28.
8
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.亚最低抑菌浓度美罗培南和环丙沙星对糖尿病足溃疡患者广泛耐药(XDR)铜绿假单胞菌分离株的疗效。
Infect Genet Evol. 2021 Aug;92:104824. doi: 10.1016/j.meegid.2021.104824. Epub 2021 Mar 25.
9
Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.采用两种方法对8种抗菌药物组合针对对妥布霉素敏感和耐药的铜绿假单胞菌菌株进行协同作用测定。
Diagn Microbiol Infect Dis. 1987 Feb;6(2):157-64. doi: 10.1016/0732-8893(87)90101-5.
10
Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.暴露于美罗培南-环丙沙星联合用药的铜绿假单胞菌的结构变化和差异表达基因。
Antimicrob Agents Chemother. 2014 Jul;58(7):3957-67. doi: 10.1128/AAC.02584-13. Epub 2014 May 5.

引用本文的文献

1
Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model.定量评估黏菌素和环丙沙星联合应用对大肠杆菌的体内药代动力学-药效学模型的综合效果。
Sci Rep. 2024 May 22;14(1):11706. doi: 10.1038/s41598-024-61518-0.
2
The Impact of Infection in Adult Cystic Fibrosis Patients-A Single Polish Centre Study.感染对成年囊性纤维化患者的影响——一项波兰单中心研究
Pathogens. 2023 Dec 12;12(12):1440. doi: 10.3390/pathogens12121440.
3
Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-Resistant Infections: A Drug Pair Limiting the Development of Resistance.环丙沙星与多粘菌素B联合用药治疗多重耐药感染:一种限制耐药性发展的药物组合。
Pharmaceutics. 2023 Feb 21;15(3):720. doi: 10.3390/pharmaceutics15030720.
4
An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin.一种用于同时分析囊性纤维化治疗药物黏菌素、依伐卡托和环丙沙星的液相色谱-串联质谱法。
J Pharm Anal. 2021 Dec;11(6):732-738. doi: 10.1016/j.jpha.2021.02.004. Epub 2021 Feb 28.
5
Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells.优化吸入性脂质体粉末制剂,并评估其在 Calu-3 人肺上皮细胞中的体外药物传递行为。
Int J Pharm. 2020 Aug 30;586:119570. doi: 10.1016/j.ijpharm.2020.119570. Epub 2020 Jun 25.
6
Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.采用体外人肺上皮细胞模型评价多黏菌素和环丙沙星脂质体共递送
Int J Pharm. 2019 Oct 5;569:118616. doi: 10.1016/j.ijpharm.2019.118616. Epub 2019 Aug 12.
7
Simultaneous Particle Size Reduction and Homogeneous Mixing to Produce Combinational Powder Formulations for Inhalation by the Single-Step Co-Jet Milling.采用单步共喷射磨技术,同时减小粒径并均匀混合,制备用于吸入的组合粉末配方。
J Pharm Sci. 2019 Sep;108(9):3146-3151. doi: 10.1016/j.xphs.2019.05.011. Epub 2019 May 18.
8
Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.脂质体制剂中共同递送环丙沙星和黏菌素,增强了对多重耐药铜绿假单胞菌的体外抗菌活性。
Pharm Res. 2018 Aug 9;35(10):187. doi: 10.1007/s11095-018-2464-8.
9
Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.协同黏菌素增强吸入型无定形环丙沙星粉末制剂的物理稳定性和雾化效果
Mol Pharm. 2018 Sep 4;15(9):4004-4020. doi: 10.1021/acs.molpharmaceut.8b00445. Epub 2018 Aug 3.
10
RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.RX-P873是一种新型蛋白质合成抑制剂,可在人THP-1单核细胞中蓄积,对革兰氏阳性菌(金黄色葡萄球菌)和革兰氏阴性菌(铜绿假单胞菌)引起的细胞内感染具有活性。
Antimicrob Agents Chemother. 2015 Aug;59(8):4750-8. doi: 10.1128/AAC.00428-15. Epub 2015 May 26.

本文引用的文献

1
Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa.铜绿假单胞菌吞噬作用和宿主清除机制。
Am J Physiol Lung Cell Mol Physiol. 2014 Apr 1;306(7):L591-603. doi: 10.1152/ajplung.00335.2013. Epub 2014 Jan 24.
2
Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.在 THP-1 人单核细胞模型中评估抗生素对铜绿假单胞菌 PAO1 的细胞内活性的药效学。
Antimicrob Agents Chemother. 2013 May;57(5):2310-8. doi: 10.1128/AAC.02609-12. Epub 2013 Mar 11.
3
In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.采用 Etest 法检测明确的碳青霉烯类耐药机制对多利培南与阿米卡星、黏菌素和左氧氟沙星体外协同作用的影响。
Diagn Microbiol Infect Dis. 2012 Dec;74(4):417-9. doi: 10.1016/j.diagmicrobio.2012.08.014. Epub 2012 Sep 17.
4
Combination therapy for treatment of infections with gram-negative bacteria.联合治疗用于治疗革兰氏阴性菌感染。
Clin Microbiol Rev. 2012 Jul;25(3):450-70. doi: 10.1128/CMR.05041-11.
5
In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.多黏菌素联合用药对多黏菌素耐药鲍曼不动杆菌、铜绿假单胞菌和肺炎克雷伯菌的体外协同作用。
Antimicrob Agents Chemother. 2012 Sep;56(9):4856-61. doi: 10.1128/AAC.05996-11. Epub 2012 Jul 2.
6
Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.联合抗生素疗法用于革兰氏阴性感染的经验性和确定性治疗:来自感染性疾病药师学会的见解。
Pharmacotherapy. 2011 Nov;31(11):1073-84. doi: 10.1592/phco.31.11.1073.
7
Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.单药治疗还是联合治疗?铜绿假单胞菌的难题。
Pharmacotherapy. 2011 Jun;31(6):598-608. doi: 10.1592/phco.31.6.598.
8
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.多黏菌素联合多利培南在体外药代动力学/药效学模型中对多重耐药铜绿假单胞菌在多个接种量下的协同杀伤作用。
Antimicrob Agents Chemother. 2011 Dec;55(12):5685-95. doi: 10.1128/AAC.05298-11. Epub 2011 Sep 12.
9
Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.临床相关的黏菌素与亚胺培南联合使用的血浆浓度可增强对多种耐药铜绿假单胞菌的药效活性,在多个接种量下。
Antimicrob Agents Chemother. 2011 Nov;55(11):5134-42. doi: 10.1128/AAC.05028-11. Epub 2011 Aug 29.
10
Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.氟喹诺酮类药物在细胞内的蓄积不能预测其细胞内活性:未感染和感染巨噬细胞的药代动力学/药效学模型中,研究加替沙星、莫西沙星和环丙沙星的结果。
Int J Antimicrob Agents. 2011 Sep;38(3):249-56. doi: 10.1016/j.ijantimicag.2011.05.011. Epub 2011 Jul 20.

在感染的THP-1单核细胞模型中,抗生素组合对铜绿假单胞菌耐药菌株的活性。

Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

作者信息

Buyck Julien M, Tulkens Paul M, Van Bambeke Françoise

机构信息

Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.

Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium

出版信息

Antimicrob Agents Chemother. 2015 Jan;59(1):258-68. doi: 10.1128/AAC.04011-14. Epub 2014 Oct 27.

DOI:10.1128/AAC.04011-14
PMID:25348528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4291360/
Abstract

Antibiotic combinations are often used for treating Pseudomonas aeruginosa infections but their efficacy toward intracellular bacteria has not been investigated so far. We have studied combinations of representatives of the main antipseudomonal classes (ciprofloxacin, meropenem, tobramycin, and colistin) against intracellular P. aeruginosa in a model of THP-1 monocytes in comparison with bacteria growing in broth, using the reference strain PAO1 and two clinical isolates (resistant to ciprofloxacin and meropenem, respectively). Interaction between drugs was assessed by checkerboard titration (extracellular model only), by kill curves, and by using the fractional maximal effect (FME) method, which allows studying the effects of combinations when dose-effect relationships are not linear. For drugs used alone, simple sigmoidal functions could be fitted to all concentration-effect relationships (extracellular and intracellular bacteria), with static concentrations close to (ciprofloxacin, colistin, and meropenem) or slightly higher than (tobramycin) the MIC and with maximal efficacy reaching the limit of detection in broth but only a 1 to 1.5 (colistin, meropenem, and tobramycin) to 2 to 3 (ciprofloxacin) log10 CFU decrease intracellularly. Extracellularly, all combinations proved additive by checkerboard titration but synergistic using the FME method and more bactericidal in kill curve assays. Intracellularly, all combinations proved additive only based on both FME and kill curve assays. Thus, although combinations appeared to modestly improve antibiotic activity against intracellular P. aeruginosa, they do not allow eradication of these persistent forms of infections. Combinations including ciprofloxacin were the most active (even against the ciprofloxacin-resistant strain), which is probably related to the fact this drug was the most effective alone intracellularly.

摘要

抗生素联合用药常用于治疗铜绿假单胞菌感染,但迄今为止其对细胞内细菌的疗效尚未得到研究。我们研究了主要抗假单胞菌类药物(环丙沙星、美罗培南、妥布霉素和黏菌素)的代表药物组合对THP-1单核细胞模型中细胞内铜绿假单胞菌的作用,与肉汤中生长的细菌进行比较,使用参考菌株PAO1和两个临床分离株(分别对环丙沙星和美罗培南耐药)。通过棋盘滴定法(仅细胞外模型)、杀菌曲线以及使用分数最大效应(FME)方法评估药物之间的相互作用,该方法允许在剂量-效应关系非线性时研究联合用药的效果。对于单独使用的药物,所有浓度-效应关系(细胞外和细胞内细菌)都可以拟合简单的S形函数,静态浓度接近(环丙沙星、黏菌素和美罗培南)或略高于(妥布霉素)最低抑菌浓度(MIC),肉汤中的最大疗效达到检测极限,但细胞内仅使细菌数量减少1至1.5(黏菌素、美罗培南和妥布霉素)至2至3(环丙沙星)个对数10CFU。在细胞外,通过棋盘滴定法所有联合用药均显示为相加作用,但使用FME方法时为协同作用,并且在杀菌曲线试验中更具杀菌作用。在细胞内,仅基于FME和杀菌曲线试验所有联合用药均显示为相加作用。因此,尽管联合用药似乎适度提高了对细胞内铜绿假单胞菌的抗生素活性,但它们并不能根除这些持续性感染形式。包括环丙沙星的联合用药最为有效(甚至对环丙沙星耐药菌株),这可能与该药物在细胞内单独使用时最有效这一事实有关。